Few people know its name, but Intuitive Surgical was one of the five best stocks of the last 20 years.
It went up as much as 18,000% in two decades.
Why?
Because it used new technology - surgical robotics - to drive sales sky high.
Now... another company is following its path.
The company is tiny today - just $500 million - but it is in position to grow dramatically.
In short, it is the inventor of the world's first AI-designed drug to enter clinical trials.
And big pharma is lining up to use its patent-protected technology.
- Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
- French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
- Bristol Meyers Squibb signed a $1.2 billion partnership with the company.
In short, the upside is MASSIVE.
Which is why I wanted to send you this video.
It comes from one of the great stock pickers of all-time - a man who actually recommended Intuitive Surgical in real time back in 2004.
In fact, he called 4 of the top 6 performing stocks from 2000 to 2020.
And he says this new company is the #1 AI Stock Under $10.
Watch his free video breaking down the situation here.
Sincerely,
Rachel Gearhart
Associate Publisher, The Oxford Club
Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.
This message is a paid advertisement sent on behalf of The Oxford Club, a third-party advertiser of Earnings360 and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States. Today's Bonus Content: AI Stock Caught Trading Under Secret Name
This message is a paid advertisement sent on behalf of The Oxford Club, a third-party advertiser of Earnings360 and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
没有评论:
发表评论